Sentiment-Signal
8,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Unternehmen & Branche
| Name | Upstream Bio, Inc. |
|---|---|
| Ticker | UPB |
| CIK | 0002022626 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 490,9 Mio. USD |
| Beta | 1,83 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 2,854,000 | -143,443,000 | -2.66 | 353,772,000 | 339,771,000 |
| 2025-09-30 | 10-Q | 683,000 | -33,748,000 | -0.63 | 391,195,000 | 378,584,000 |
| 2025-06-30 | 10-Q | 937,000 | -39,966,000 | -0.74 | 420,521,000 | 408,743,000 |
| 2025-03-31 | 10-Q | 566,000 | -27,270,000 | -0.51 | 456,169,000 | 445,610,000 |
| 2024-12-31 | 10-K | 2,370,000 | -62,806,000 | -5.58 | 481,719,000 | 469,852,000 |
| 2024-09-30 | 10-Q | 607,000 | -15,992,000 | -6.96 | 232,700,000 | -160,311,000 |
| 2024-06-30 | 10-Q | 510,000 | -14,678,000 | -6.50 | -146,607,000 | |
| 2024-03-31 | 10-Q | 640,000 | -10,894,000 | -4.68 | -133,407,000 | |
| 2023-12-31 | 10-K | 2,380,000 | -20,537,000 | -12.95 | 117,198,000 | -123,126,000 |
| 2023-09-30 | 10-Q | 621,000 | -3,102,000 | -2.11 | -112,204,000 | |
| 2023-06-30 | 10-Q | -2,540,000 | -109,866,000 | |||
| 2023-03-31 | 10-Q | -3,062,000 | -107,913,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Sutherland Everett Rand | Director, Officer, Chief Executive Officer | Open Market Sale | -2,093 | 9.29 | -19,443.97 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.